Description of Business	9 Months Ended
Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business	Description of Business Organization and Nature of Operations Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company. References in this Quarterly Report to “us,” “we,” “our,” the “Company,” or “Lumos” are to Lumos Pharma, Inc. and its wholly-owned subsidiaries. With our principal executive offices located in Austin, Texas and additional executive and administrative offices located in Ames, Iowa, we are engaged in advancing our clinical program and focused on identifying, acquiring, developing, and commercializing novel products and new therapies for people with rare diseases on a global level, for which there is currently a significant unmet need for safe and effective therapies. Our common stock is listed on the Nasdaq Global Market (“Nasdaq”) and trades under the ticker symbol “LUMO.” The Company entered into a business combination (the “Merger”) between the Company, formerly known as NewLink Genetics Corporation (“NewLink”), Cyclone Merger Sub, Inc. (“Merger Sub”), a wholly owned subsidiary of NewLink, and Lumos Pharma, Inc., which has since been renamed “Lumos Pharma Sub, Inc.” (“Private Lumos”). The Merger closed on March 18, 2020, and Merger Sub merged with and into Private Lumos, with Private Lumos surviving as a wholly-owned subsidiary of the Company. After the consummation of the Merger, the combined company has focused its efforts on the development of Private Lumos’ sole product candidate, secretagogue ibutamoren (“LUM-201”), a potential oral therapy for idiopathic pediatric growth hormone deficiency (“PGHD”) and other rare endocrine disorders. 2024 Merger Agreement and Related Transactions On October 23, 2024, the Company announced that it had entered into a definitive merger agreement, dated October 22, 2024 (the “2024 Merger Agreement”) whereby Double Point Ventures LLC (“DPV”), through its wholly-owned subsidiary, DPV Parent, Inc. (“Parent”), will acquire 100% of the Company's outstanding shares of common stock for $4.25 per share in cash, plus one non-transferable, unsecured contingent value right (“CVR”) per share with certain payments payable on achievement of certain milestones (the “2024 Merger”). The 2024 Merger is structured as a tender offer (the “Offer”) by a wholly owned subsidiary of Parent (“DPV Merger Sub”) for 100% of the outstanding shares of common stock of the Company for (i) $4.25 per share in cash at closing and (ii) one CVR for each share of common stock outstanding, representing the future right to receive additional contingent cash payments upon the achievement of certain milestone events described below. There can be no assurance any payments will be made with respect to the CVRs. In addition to any cash portion payable to each In-the-Money Option and Company Stock Right (each term as defined in the 2024 Merger Agreement) pursuant to the terms of the 2024 Merger Agreement, each In-the-Money Option and Company Stock Right will receive one CVR for each Share underlying such In-the-Money Option and Company Stock Right, respectively. At or prior to the effective time of the 2024 Merger (the “Effective Time”), Parent expects to enter into a Contingent Value Rights Agreement (the “CVR Agreement”) with a rights agent (the “Rights Agent”) and a representative, agent and attorney in-fact of the holders of CVRs (“CVR Holders”). Each CVR represents the contractual right to receive certain contingent cash payments equal to “CVR Proceeds” calculated as follows: i.upon the first achievement of Annual Global Net Revenue (as defined in the CVR Agreement) in a fiscal year equal to or greater than (a) $500 million, (b) $1 billion, and/or (c) $1.5 billion, a price of $1.00 per share, $1.50 per share, and $2.00 per share, respectively, each calculated during the period beginning on the closing of the 2024 Merger (the “2024 Merger Closing”) and ending on December 31, 2037; ii.following the execution of any definitive agreement or series of agreements with any third party (excluding any Company Sale (as defined in the CVR Agreement)), that occurs during the period beginning on the 2024 Merger Closing and ending on the 18-month anniversary of the 2024 Merger Closing, with respect to the sale, assignment, transfer, license, option, non-assert or other disposition of Lumos’s assets acquired by DPV Merger Sub (a) for any exploitation in the cardiometabolic field, or (b) excluding LUM-201, in any other field (each of (a) and (b), a “Transaction”), an amount in cash per CVR equal to 25% of Transaction Proceeds (as defined in the CVR Agreement) after deduction of an amount equal to (a) 50% of the Upfront Cash Consideration (as defined in the CVR Agreement) plus (b) all amounts contributed by Parent in the form or equity investments or loans (including the CTF Agreement (as defined below)) to Lumos to develop the assets involved in the Transactions, allocated pro rata among all CVR Holders and paid as a separate CVR for each Measurement Period (as defined in the CVR Agreement); and iii.upon the consummation, in a single transaction or in a series of related transactions, that occurs during the period beginning on the 2024 Merger Closing and ending on the 18-month anniversary of the 2024 Merger Closing, of any one or more of the following events: (a) acquisition of direct or indirect beneficial ownership of more than 50% of the outstanding shares of capital stock of the Company by a unrelated third party or (b) sale, assignment, lease, exclusive license or other disposition of all or substantially all of the assets or business of the Company to an unrelated third party, a price per share of $2.00 per share. The right to the contingent payments contemplated by the CVR Agreement is a contractual right only and will not be transferable, except in the limited circumstances specified in the CVR Agreement. The CVRs will not be evidenced by a certificate or any other instrument and will not be registered with the SEC. The CVRs will not have any voting or dividend rights and will not represent any equity or ownership interest in Purchaser (and, following the Effective Time, the surviving corporation) or any of its affiliates. No interest will accrue on any amounts payable in respect of the CVRs. Following a thorough review of financing and strategic alternatives, the Company’s Board of Directors (the “Board”), with the assistance of the Board’s legal and financial advisors, unanimously determined that the acquisition by DPV is in the best interests of all the Company's stockholders, has approved the 2024 Merger Agreement and related transactions, and unanimously recommends that the Company’s stockholders tender their shares in the Offer. The transaction is expected to close before the end of 2024, subject to the satisfaction or waiver of certain closing conditions including the tender of the Company's common stock representing at least a majority of the total number of outstanding shares. The Company's officers, directors and stockholders collectively holding approximately 17.7% of the Company's common stock have signed tender and support agreements under which such parties have agreed to tender their shares in the Offer and support the merger transaction. The transactions contemplated by the 2024 Merger Agreement are not subject to any financing condition and DPV will fund the transactions from its existing cash resources. Upon completion of the 2024 Merger, the Company will continue as an indirect wholly-owned subsidiary of DPV, and operate as a standalone business of DPV, from the Company's headquarters in Austin, Texas. Simultaneously with the execution of the 2024 Merger Agreement, DPV and the Company entered into a Clinical Trial Funding Agreement (the “CTF Agreement”), pursuant to which DPV has agreed to loan up to $7.5 million to the Company solely for the purpose of funding certain research and development expenses, as set forth in the CTF Agreement and as mutually agreed upon by DPV and the Company, during the period beginning on the execution of the 2024 Merger Agreement and ending on the earlier of (a) the closing of the 2024 Merger or (b) the termination of the 2024 Merger Agreement for any reason. Pursuant to the CTF Agreement, the Company may draw down funds by providing advance written notice to DPV of the amount required, the third-party provider to whom the Company will pay such funds, and any supporting documentation as DPV may reasonably request. The Company will further provide DPV with confirmation of payment made to the third-party provider within three business days of receipt of the funds from DPV. Any amounts loaned to the Company under the CTF Agreement shall be evidenced by a secured promissory note senior to any other indebtedness or obligations of the Company. Liquidity and Going Concern The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The financial statements also do not reflect any adjustments relating to the recoverability and reclassifications of assets and liabilities that might be necessary if the Company is unable to continue as a going concern. The Company has historically devoted substantially all of its efforts toward research and development and has never earned revenue from commercial sales of its products. Management expects to continue to incur additional substantial losses in the foreseeable future as a result of the Company’s research and development activities. As of September 30, 2024, the Company had approximately $13.5 million of cash and cash equivalents. The Company's accumulated deficit at September 30, 2024 was approximately $187.0 million. Based on the Company's current cash forecast and the Company’s dependence on its ability to obtain additional financing to fund its operations in advancing the PGHD program into a Phase 3 trial, the Company concluded that its available cash and cash equivalents as of September 30, 2024 may not be sufficient to fund its operations for at least 12 months from the filing date of this Quarterly Report, and thus substantial doubt exists as to the Company’s ability to continue as a going concern. Although management plans to complete the 2024 Merger in a timely manner, there can be no assurances that the 2024 Merger will close or, if it does close, that it would provide sufficient financing to continue operations. If the 2024 Merger does not close for any reason, there can be no assurance that any other financing will be available on terms that are favorable to the Company, or at all. The Company has taken certain steps to delay or reduce the scope of its research programs and limit its operations until it is able to obtain additional funding. If the 2024 Merger does not close, the Company will be forced to further delay or reduce the scope of its research programs, including its LUM-201 Phase 3 trial, and/or limit or cease its operations.

Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company. References in this Quarterly Report to “us,” “we,” “our,” the “Company,” or “Lumos” are to Lumos Pharma, Inc. and its wholly-owned subsidiaries. With our principal executive offices located in Austin, Texas and additional executive and administrative offices located in Ames, Iowa, we are engaged in advancing our clinical program and focused on identifying, acquiring, developing, and commercializing novel products and new therapies for people with rare diseases on a global level, for which there is currently a significant unmet need for safe and effective therapies. Our common stock is listed on the Nasdaq Global Market (“Nasdaq”) and trades under the ticker symbol “LUMO.”

The Company entered into a business combination (the “Merger”) between the Company, formerly known as NewLink Genetics Corporation (“NewLink”), Cyclone Merger Sub, Inc. (“Merger Sub”), a wholly owned subsidiary of NewLink, and Lumos Pharma, Inc., which has since been renamed “Lumos Pharma Sub, Inc.” (“Private Lumos”). The Merger closed on March 18, 2020, and Merger Sub merged with and into Private Lumos, with Private Lumos surviving as a wholly-owned subsidiary of the Company.

After the consummation of the Merger, the combined company has focused its efforts on the development of Private Lumos’ sole product candidate, secretagogue ibutamoren (“LUM-201”), a potential oral therapy for idiopathic pediatric growth hormone deficiency (“PGHD”) and other rare endocrine disorders.

On October 23, 2024, the Company announced that it had entered into a definitive merger agreement, dated October 22, 2024 (the “2024 Merger Agreement”) whereby Double Point Ventures LLC (“DPV”), through its wholly-owned subsidiary, DPV Parent, Inc. (“Parent”), will acquire 100% of the Company's outstanding shares of common stock for $4.25 per share in cash, plus one non-transferable, unsecured contingent value right (“CVR”) per share with certain payments payable on achievement of certain milestones (the “2024 Merger”).

The 2024 Merger is structured as a tender offer (the “Offer”) by a wholly owned subsidiary of Parent (“DPV Merger Sub”) for 100% of the outstanding shares of common stock of the Company for (i) $4.25 per share in cash at closing and (ii) one CVR for each share of common stock outstanding, representing the future right to receive additional contingent cash payments upon the achievement of certain milestone events described below. There can be no assurance any payments will be made with respect to the CVRs. In addition to any cash portion payable to each In-the-Money Option and Company Stock Right (each term as defined in the 2024 Merger Agreement) pursuant to the terms of the 2024 Merger Agreement, each In-the-Money Option and Company Stock Right will receive one CVR for each Share underlying such In-the-Money Option and Company Stock Right, respectively.

At or prior to the effective time of the 2024 Merger (the “Effective Time”), Parent expects to enter into a Contingent Value Rights Agreement (the “CVR Agreement”) with a rights agent (the “Rights Agent”) and a representative, agent and attorney in-fact of the holders of CVRs (“CVR Holders”). Each CVR represents the contractual right to receive certain contingent cash payments equal to “CVR Proceeds” calculated as follows:

i.upon the first achievement of Annual Global Net Revenue (as defined in the CVR Agreement) in a fiscal year equal to or greater than (a) $500 million, (b) $1 billion, and/or (c) $1.5 billion, a price of $1.00 per share, $1.50 per share, and $2.00 per share, respectively, each calculated during the period beginning on the closing of the 2024 Merger (the “2024 Merger Closing”) and ending on December 31, 2037;

ii.following the execution of any definitive agreement or series of agreements with any third party (excluding any Company Sale (as defined in the CVR Agreement)), that occurs during the period beginning on the 2024 Merger Closing and ending on the 18-month anniversary of the 2024 Merger Closing, with respect to the sale, assignment, transfer, license, option, non-assert or other disposition of Lumos’s assets acquired by DPV Merger Sub (a) for any exploitation in the cardiometabolic field, or (b) excluding LUM-201, in any other field (each of (a) and (b), a “Transaction”), an amount in cash per CVR equal to 25% of Transaction Proceeds (as defined in the CVR Agreement)

after deduction of an amount equal to (a) 50% of the Upfront Cash Consideration (as defined in the CVR Agreement) plus (b) all amounts contributed by Parent in the form or equity investments or loans (including the CTF Agreement (as defined below)) to Lumos to develop the assets involved in the Transactions, allocated pro rata among all CVR Holders and paid as a separate CVR for each Measurement Period (as defined in the CVR Agreement); and

iii.upon the consummation, in a single transaction or in a series of related transactions, that occurs during the period beginning on the 2024 Merger Closing and ending on the 18-month anniversary of the 2024 Merger Closing, of any one or more of the following events: (a) acquisition of direct or indirect beneficial ownership of more than 50% of the outstanding shares of capital stock of the Company by a unrelated third party or (b) sale, assignment, lease, exclusive license or other disposition of all or substantially all of the assets or business of the Company to an unrelated third party, a price per share of $2.00 per share.

The right to the contingent payments contemplated by the CVR Agreement is a contractual right only and will not be transferable, except in the limited circumstances specified in the CVR Agreement. The CVRs will not be evidenced by a certificate or any other instrument and will not be registered with the SEC. The CVRs will not have any voting or dividend rights and will not represent any equity or ownership interest in Purchaser (and, following the Effective Time, the surviving corporation) or any of its affiliates. No interest will accrue on any amounts payable in respect of the CVRs.

Following a thorough review of financing and strategic alternatives, the Company’s Board of Directors (the “Board”), with the assistance of the Board’s legal and financial advisors, unanimously determined that the acquisition by DPV is in the best interests of all the Company's stockholders, has approved the 2024 Merger Agreement and related transactions, and unanimously recommends that the Company’s stockholders tender their shares in the Offer. The transaction is expected to close before the end of 2024, subject to the satisfaction or waiver of certain closing conditions including the tender of the Company's common stock representing at least a majority of the total number of outstanding shares.

The Company's officers, directors and stockholders collectively holding approximately 17.7% of the Company's common stock have signed tender and support agreements under which such parties have agreed to tender their shares in the Offer and support the merger transaction.

The transactions contemplated by the 2024 Merger Agreement are not subject to any financing condition and DPV will fund the transactions from its existing cash resources. Upon completion of the 2024 Merger, the Company will continue as an indirect wholly-owned subsidiary of DPV, and operate as a standalone business of DPV, from the Company's headquarters in Austin, Texas.

Simultaneously with the execution of the 2024 Merger Agreement, DPV and the Company entered into a Clinical Trial Funding Agreement (the “CTF Agreement”), pursuant to which DPV has agreed to loan up to $7.5 million to the Company solely for the purpose of funding certain research and development expenses, as set forth in the CTF Agreement and as mutually agreed upon by DPV and the Company, during the period beginning on the execution of the 2024 Merger Agreement and ending on the earlier of (a) the closing of the 2024 Merger or (b) the termination of the 2024 Merger Agreement for any reason. Pursuant to the CTF Agreement, the Company may draw down funds by providing advance written notice to DPV of the amount required, the third-party provider to whom the Company will pay such funds, and any supporting documentation as DPV may reasonably request. The Company will further provide DPV with confirmation of payment made to the third-party provider within three business days of receipt of the funds from DPV. Any amounts loaned to the Company under the CTF Agreement shall be evidenced by a secured promissory note senior to any other indebtedness or obligations of the Company.

The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The financial statements also do not reflect any adjustments relating to the recoverability and reclassifications of assets and liabilities that might be necessary if the Company is unable to continue as a going concern. The Company has historically devoted substantially all of its efforts toward research and development and has never earned revenue from commercial sales of its products. Management expects to continue to incur additional substantial losses in the foreseeable future as a result of the Company’s research and development activities.

As of September 30, 2024, the Company had approximately $13.5 million of cash and cash equivalents. The Company's accumulated deficit at September 30, 2024 was approximately $187.0 million. Based on the Company's current cash forecast and the Company’s dependence on its ability to obtain additional financing to fund its operations in advancing the PGHD program into a Phase 3 trial, the Company concluded that its available cash and cash equivalents as of September 30, 2024 may not be sufficient to fund its operations for at least 12 months from the filing date of this Quarterly Report, and thus substantial doubt exists as to the Company’s ability to continue as a going concern.